Category C—Although animal data suggest risk, the absence of detailed human pregnancy experience prevents an assessment of the embryo-fetal risk, ∴ safest course is to avoid the drug in pregnancy.
No reports describing the use of atomoxetine during human lactation have been located however the molecular weight of the parent drug and the relatively long t½ suggest that the drug and/or its metabolites will be excreted into breast milk.
The safety, efficacy and pharmacokinetics in geriatric patients have not been evaluated.
No dosage adjustment necessary.
Moderate hepatic impairment (Child-Pugh B): ↓ dose 50%; severe hepatic impairment (Child-Pugh C): ↓ dose 25%